Alex Goldberg

Prana Biotechnology Limited (NASDAQ:PRAN) and Amazon.com Inc. (NASDAQ:AMZN) Added to Equity Profile Report's NASDAQ Active Stock Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 12/09/2013 -- Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding Prana Biotechnology Limited (NASDAQ:PRAN) and Amazon.com Inc. (NASDAQ:AMZN).

Prana Biotechnology Limited (NASDAQ:PRAN) a company that researches and develops therapeutic drugs for the treatment of neurological disorders in Australia closed up in its previous session (+16.46%) on 5,301,418 shares traded after Prana Completed PBT2 Dosing in IMAGINE Alzheimer's Disease Clinical Trial. Prana Biotechnology Limited (NASDAQ:PRAN) is currently up (+268.47%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Prana Biotechnology Limited (NASDAQ:PRAN)

Amazon.com Inc. (NASDAQ:AMZN) a company that operates as an online retailer in North America and internationally closed down in its previous session (-0.53%) on 2,761,117 shares traded after eBay CEO described Amazon's drone delivery plan as a long-term fantasy. Amazon.com Inc. (NASDAQ:AMZN) is currently down (-4.12%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Amazon.com Inc. (NASDAQ:AMZN)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com